Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan AnemiaCAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum...
Staff
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
New 30-month data from the GALE long-term extension study of SYFOVRE® (pegcetacoplan injection) to be presentedWALTHAM, Mass., July 10, 2023...
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for...
Mendus AB: Report from the extraordinary general meeting of Mendus AB (publ) on 10 July 2023
At the extraordinary general meeting (the “EGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 10 July 2023...
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan
The two industry leaders focus on navigating the biotech industry and immuno-oncology researchLEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) --...
Safe group group reports half-year revenues of €2.9m
Safe group group reports half-year revenues of €2.9m Second-quarter revenue of €1.4M in Q2 2022, stable compared with Q1...
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a...
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
Press ReleaseNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNCX 470 therapeutic profile positively received...
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARAInitial data expected in Q4...
BioSenic provides further update on negotiations with its main creditors
INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10th,...
BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call
July 7, 2023News Release BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call COPENHAGEN, Denmark and BOSTON,...
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered...
SmileDirectClub to Report Second Quarter 2023 Results on August 8, 2023
NASHVILLE, Tenn., July 07, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the...
Xtant Medical Announces Closing of $15 Million Private Placement
BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company...
European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys'...
AMN Healthcare to Hold Second Quarter 2023 Earnings Conference Call on Thursday, August 3, 2023
DALLAS, July 07, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss...
Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS7 July 2023 at 14.30 EEST Orion Corporation: Change in...
Advanced FDA Cleared Magstim Horizon 3.0 Transcranial Magnetic Stimulation Now Available in United Kingdom
Approval by UKCA Empowers UK Physicians to Advance Care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with...
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...